
To evaluate the efficacy and zzso of the P zzso zzso zzso zzso zzso 

zzso zzso zzso clinical zzso 

Clinical research zzso 

zzso women with symptomatic zzso zzso 

zzso oral zzso (10 or 20 zzso or zzso zzso for 12 weeks zzso zzso A second zzso treatment with zzso zzso 2) was zzso A computer-generated blocked zzso was zzso 

zzso resonance imaging zzso total zzso volume zzso change was the primary zzso zzso and quality of life zzso were secondary end zzso 

Treatment 1 zzso increased zzso in the zzso group, but decreased zzso and zzso in the zzso and zzso zzso The zzso decreased further in treatment 2 zzso zzso occurred in zzso women taking zzso and none on zzso zzso resumed after zzso zzso improved only with zzso zzso zzso zzso to zzso zzso zzso zzso as did the zzso zzso zzso symptom severity, zzso and concern zzso and overall zzso zzso The zzso was well zzso with no serious adverse zzso zzso events were unchanged during zzso 

Administration of zzso for 3-6 months controls zzso reduces zzso size, and improves zzso 

